ArticleFrontiers in oncology2026

HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report.

Mansi Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.